Search Results - thomas+spies

3 Results

Sort By:

NKG2D Biologic to Reduce Immune Cell Activation A multimeric decoy to block activation of NKG2D and treat autoimmune and inflammatory diseases, and for use in vaccine development. Dr. Roland Strong and Dr. Martin Prlic have developed a multimeric NKG2D decoy that will bind all NKG2D ligands and block the NKG2D pathway. NKG2D is a receptor...

Published: 12/27/2023 | Updated: 10/21/2019 | Inventor(s): Roland Strong, Martin Prlic, Mesfin Gewe, Thomas Spies, Veronika Groh-Spies, Peter Rupert

Keywords(s): Protein / Peptide

Category(s): Therapeutic, Vaccine

Immunostimulatory Capacity of Two Anti-Human NKG2D Monoclonal Antibodies

Monoclonal NKG2D Antibodies for the Treatment of Autoimmune and Inflammatory Disorders Two anti-human NKG2D monoclonal antibodies to specifically target and/or inhibit the NKG2D receptor on immune cells (e.g., CD4+ T cells). A precise balance of effector T cell activity is required to maintain effective immune surveillance without initiating...

Published: 4/6/2025 | Updated: 10/2/2019 | Inventor(s): Thomas Spies, Veronika Groh-Spies

Keywords(s): Hybridoma / Antibody

Category(s): Therapeutic

Cancer expression of the NKG2D lymphocyte receptor together with its ligands and promotion of tumorigenesis

NKG2D-Targeted Therapy for Ovarian Cancer Therapeutic for ovarian cancer that targets NKG2D ligands and prevents binding and stimulating the NKG2D receptor. Normally expressed by immune cells, subsets of human cancer cells co-opt expression of the NKG2D receptor to exploit the presence of its ligands on cancer cells for oncogenic/tumorigenic...

Published: 12/26/2023 | Updated: 5/17/2017 | Inventor(s): Thomas Spies, Veronika Groh-Spies

Keywords(s): Protein / Peptide, Target

Category(s): Therapeutic